Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy -: A randomized study

被引:26
作者
Yalçin, S [1 ]
Tekuzman, G [1 ]
Baltali, E [1 ]
Özisik, Y [1 ]
Barista, I [1 ]
机构
[1] Hacettepe Univ, Dept Med Oncol, Inst Oncol, TR-06100 Ankara, Turkey
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1999年 / 22卷 / 01期
关键词
ondansetron; tropisetron; granisetron; acute and delayed vomiting; chemotherapy;
D O I
10.1097/00000421-199902000-00023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this randomized study, the efficacy of a single dose of three serotonin antagonists were compared in prophylaxis of acute and delayed vomiting induced by moderately emetogenic, single-day chemotherapy in chemotherapy-naive patients. A total of 54 patients were entered. Eighteen patients received ondansetron, 17 received tropisetron, and 19 received granisetron. Antiemetics were administered as 15-minute intravenous infusion before chemotherapy. Complete control of acute vomiting was achieved in 38.8% with ondansetron, 58.84% with tropisetron, and 73.7% with granisetron. Major response rates were 83.3%, 82.3%, and 89.5%, respectively. For the delayed control of emesis, complete control of delayed vomiting was achieved in 38.8% with ondansetron. 52.9% with tropisetron, and 73.7% with granisetron. The major response rates were 71.8%, 70.5%, and 100%, respectively. The adverse effects were rare and mild in all groups. The authors conclude that there may be clinically important differences among serotonin antagonists used for chemotherapy-induced emesis.
引用
收藏
页码:94 / 96
页数:3
相关论文
共 18 条
[1]   THE 5-HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS AS ANTIEMETICS - PRECLINICAL EVALUATION AND MECHANISM OF ACTION [J].
ANDREWS, PLR ;
BHANDARI, P .
EUROPEAN JOURNAL OF CANCER, 1993, 29A :S11-S16
[2]  
ANDREWS PLR, 1990, J PHYSL, V422, P42
[3]  
ANDREWS PLR, 1990, EUR J CANCER S1, V422, P42
[4]   TROPISETRON PLUS HALOPERIDOL TO AMELIORATE NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE ALKYLATING AGENT CANCER-CHEMOTHERAPY [J].
BREGNI, M ;
SIENA, S ;
DINICOLA, M ;
BONADONNA, G ;
GIANNI, AM .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :561-565
[5]   ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[6]   PHARMACOLOGIC TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING [J].
FIORE, JJ ;
GRALLA, RJ .
CANCER INVESTIGATION, 1984, 2 (05) :351-361
[7]   ANTIEMETIC TREATMENT FOR CANCER-CHEMOTHERAPY - PROBLEMS AND PROGRESS [J].
GRALLA, RJ .
SUPPORTIVE CARE IN CANCER, 1994, 2 (05) :275-276
[8]   5-HT(3) RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OF ACUTE VOMITING INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY - A RANDOMIZED STUDY [J].
JANTUNEN, IT ;
MUHONEN, TT ;
KATAJA, VV ;
FLANDER, MK ;
TEERENHOVI, L .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (12) :1669-1672
[9]   COMPARISON OF DEXAMETHASONE AND ONDANSETRON IN THE PROPHYLAXIS OF EMESIS INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY [J].
JONES, AL ;
HILL, AS ;
SOUKOP, M ;
HUTCHEON, AW ;
CASSIDY, J ;
KAYE, SB ;
SIKORA, K ;
CARNEY, DN ;
CUNNINGHAM, D .
LANCET, 1991, 338 (8765) :483-487
[10]  
Mantovani G, 1996, CANCER, V77, P941, DOI 10.1002/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.3.CO